Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9587346 | 0.84 | TDP1 (0.52) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL7685903 | 0.84 | KMT2A (0.63) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL28141574 | 0.84 | ACHE (0.50) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL27856614 | 0.84 | ALDH1A1 (0.51) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL13886462 | 0.83 | DCPS (0.50) | DCPSDHFR | |
| SCHEMBL9588295 | 0.80 | ACHE (0.47) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL9587522 | 0.80 | ABCG2 (0.48) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL2986361 | 0.80 | ACHE (0.47) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL8471116 | 0.80 | ACHE (0.47) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL21612802 | 0.79 | ALDH1A1 (0.52) | ACHEALDH1A1TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462528-A | 6, 8-Dinitroquinazoline-2, 4 (1H, 3H) -diketone energetic compound and synthetic method thereof | 南京理工大学 | 2025-02-18 | — | — | CN | claimed |
| US-7060825-B2 | Process for synthesizing 6-quinazolinyl-ethyl-benzoyl and related antifolates | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | claimed |
| CN-119462528-B | 6, 8-Dinitroquinazoline-2, 4 (1H, 3H) -diketone energetic compound and synthetic method thereof | 南京理工大学 | 2025-12-26 | — | — | CN | disclosed |
| CN-119462528-A | 6, 8-Dinitroquinazoline-2, 4 (1H, 3H) -diketone energetic compound and synthetic method thereof | 南京理工大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-119462528-A | 6, 8-Dinitroquinazoline-2, 4 (1H, 3H) -diketone energetic compound and synthetic method thereof | 南京理工大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-106905247-B | Acetamides and application thereof | 华东理工大学 | 2019-05-17 | — | — | CN | disclosed |
| WO-2009049421-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ENZYME ACTIVITY IN GAUCHER, GM1-GANGLIOSIDOSIS/MORQUIO B DISEASE, AND PARKINSON'S DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009049422-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ENZYME ACTIVITY IN GAUCHER, GM1 -GANGLIOSIDOSIS/MORQUIO B DISEASE. AND PARKINSON'S DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009049422-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ENZYME ACTIVITY IN GAUCHER, GM1 -GANGLIOSIDOSIS/MORQUIO B DISEASE. AND PARKINSON'S DISEASE | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-04-23 | — | — | WO | disclosed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| US-7060825-B2 | Process for synthesizing 6-quinazolinyl-ethyl-benzoyl and related antifolates | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-7060825-B2 | Process for synthesizing 6-quinazolinyl-ethyl-benzoyl and related antifolates | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050020833-A1 | Process for synthesizing antifolates | BIONUMERIK PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| WO-1993013079-A1 | ANTIFOLATE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| EP-0253396-B1 | PROCESS FOR PREPARING 5,6-SUBSTITUTED-2,4-QUINAZOLINEDIAMINES AND INTERMEDIATES | WARNER-LAMBERT COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| CN-1049498-A | 2,4-diamino-5-replacement-6-(N-replaces benzyl amino) quinazoline derivant is synthetic | SHANGHAI INST PHARM INDUSTRY (CN) | 1991-02-27 | — | — | CN | disclosed |
| EP-0253396-A2 | Process for preparing 5,6-substituted-2,4-quinazolinediamines and intermediates | WARNER-LAMBERT COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
| US-4677219-A | Substituted benzonitriles | WARNER-LAMBERT COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | ACHE 1090/4885ALDH1A1 2395/4885TDP1 909/4885 |
| US-20050020833-A1 | Process for synthesizing antifolates | DHFR, FDPS, FOLR1 | ACHE 3918/4885ALDH1A1 2024/4885TDP1 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.